UK Markets closed

DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference

Montrouge, France, February 1, 2019

DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will present at the 8th Annual Leerink Partners Global Healthcare Conference in New York, NY, on Thursday, February 28, 2019, at 10:30am EST.

A live webcast of the presentation will be available on the Investors & Media section of the Company`s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV`s website within three hours after the event.

About DBV Technologies 

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV`s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV`s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, Summit, NJ and New York, NY. The Company`s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company`s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (DBVT).

DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com

DBV Media Contact
Joe Becker
VP, Global Corporate Communications
+1-646-650-3912
joseph.becker@dbv-technologies.com

PDF Version


This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire

HUG#2233102